() experienced a significant decline in short interest throughout the month of March. On April 15, there were 182,100 short shares, which is a decrease of 24,9% compared to the total of 242,600 on March 31st. The short-interest rate is currently 0.1 day based on an average trading volume 1,310,000 shares. About 1.0% of a company's stock is short sold.
Sera Prognostications: Institutional Investors' Views
Several hedge funds and institutional investors recently changed their holdings in the stock. BlackRock Inc. has increased its Sera Prognostics holdings by 4.9% in the first quarter. BlackRock Inc. owns 186.140 shares worth $707,00 after buying an additional 8,718 during the period. Vanguard Group Inc. has increased its holdings of Sera Prognostics from 7.0% to $713,000 during the first quarter. Vanguard Group Inc. owns 188.127 shares worth $713,000, after buying an additional 12,324 during the period. Frontier Wealth Management LLC acquired a new Sera Prognostics position during the first quarter, valued at approximately $30,000. Charles Schwab Investment Management Inc. bought a new Sera Prognostics position during the first quarter worth about $68,000. Northern Trust Corp also increased its holdings of Sera Prognostics during the first quarter by 54.6%. Northern Trust Corp owns 56.512 shares worth $214,000, after buying an additional 19.948 shares. During Friday's midday trading, the company gained $0.05 to reach $3.35. The trading volume was 32,824 versus the average of 33,116. Sera Prognostics's low for the past year was $1.10, and its high is $4.25. The company's quick ratio is 5.80, its current ratio is 5.80, and it has a debt to equity ratio of 0.01. The company's 50-day moving price is $3.69, and its 200 day moving price is $2.23. The market cap is $103.92m, the PE ratio is -2.34, and beta is 0.30.
The company last announced its results on March 22nd. The company's ($0.31) per share earnings for the quarter beat analysts' consensus estimates ($0.42) ($0.11) by $0.11. Sera Prognostics reported a negative return of equity of 39.26%, and a net margin of 16.487.31%. The company's revenue was $0.07 million, which is lower than the analyst estimate of $0.13. Analysts expect Sera Prognostics to post an average of -1.55 earnings-per-share for the current fiscal year.
Sera Prognostics Company Profile
Sera Prognostics, Inc, is a women's healthcare diagnostic company that discovers, develops, commercializes and improves pregnancy outcomes with biomarker testing. PreTRM is a biomarker-based blood test that predicts the risk of spontaneous premature birth in singleton pregnancy.
MarketBeat.com offers a FREE daily email newsletter